STOCK TITAN

Xencor Inc - XNCR STOCK NEWS

Welcome to our dedicated news page for Xencor (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xencor's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xencor's position in the market.

Rhea-AI Summary
Xencor, Inc. (NASDAQ: XNCR) will release its third quarter 2023 financial results on November 7, 2023, after the market closes. A webcast and conference call will be held at 4:30 p.m. ET to discuss the results and provide a corporate update. The live webcast can be accessed through the Company's website, and a recording will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
conferences earnings
-
Rhea-AI Summary
Xencor CFO John J. Kuch plans to retire in March 2024 after a 23-year career with the company. He will support the search for a new CFO and enter into a consulting agreement. Xencor's CEO thanks Kuch for his leadership and contributions to the company's growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
Rhea-AI Summary
Xencor, Inc. announces three poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
conferences
Rhea-AI Summary
Xencor, Inc. appoints Barbara J. Klencke, M.D. to its board of directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
management
Xencor Inc

Nasdaq:XNCR

XNCR Rankings

XNCR Stock Data

1.25B
55.23M
0.98%
105.64%
9.71%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Monrovia

About XNCR

antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product